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JC polyomavirus (JCPyV) persists in up to 90% of the global human population. In healthy
individuals, the virus resides within the kidneys resulting in a low-level infection. However, in
severely immunocompromised individuals, the virus can migrate to the central nervous system
(CNS), causing the demyelinating disease progressive multifocal leukoencephalopathy (PML).
Currently, this debilitating disease has no clinical therapeutic options and is almost universally
fatal. Specifics of the JCPyV infectious cycle, as well as the limitations of traditional laboratory
techniques, have previously hindered the search for antiviral agents with the potential to
prevent or treat JCPyV infection. To this end, a new high-throughput, in vitro method to
measure JCPyV infectivity, the In-cell Western (ICW) assay, has been adapted to allow for rapid,
consistent, and impartial analysis of the antiviral properties of large libraries of drugs and other
small compounds. Utilizing this ICW platform, a large-scale drug screen was performed using
the National Institute for Health (NIH) Clinical Collection, a library of over 700 drugs and small
compounds, to identify drugs and compounds that reduce JCPyV infectivity. Through analysis
and characterization of these compounds, heretofore unknown therapeutic agents against
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JCPyV have been identified, including drugs that target cell surface receptors and biochemical
pathways involved in calcium and mitogen-activated protein (MAP) kinase signaling. These
compounds are the focus of further characterization to identify the cell-based mechanism by
which they inhibit JCPyV infection. Findings from this study provide new information that
significantly advances the field in the development of antiviral compounds to treat or prevent
PML.
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CHAPTER 1
INTRODUCTION
1.1. JC Polyomavirus Disease
Polyomaviridae is a large family of viruses that includes 14 species capable of infecting
human hosts [1]. Infection by a number of these viruses is known to cause or contribute to
human pathologies including different types of cancers, respiratory illnesses, diseases of the
kidney and bladder, as well as a fatal, neurological condition known as progressive multifocal
leukoencephalopathy (PML) [2]. PML is the result of neuron demyelination within the brain due
to the lytic infection of oligodendrocytes. The destruction of these glial cells prevents proper
nerve function and the subsequent formation of plaques within the brain (Figure 1), leading to
the loss of cognitive, sensory, and motor functions as the disease progresses. Ultimately, this
results in the afflicted individual’s death, typically within a few months to one year of symptom
onset [3]. Survival rates for patients suffering from PML have increased as the progression of
the disease has become more understood and methods of early detection and effective highly
active antiretroviral therapies (HAART) have been established [4]. However, survivability and
the level of disability or impairment in these patients is based on a number of factors including
age, degree of symptom onset, and general response to the treatment of the underlying
immune compromise [5, 6].
The causative agent of this debilitating disease, JC polyomavirus (JCPyV), was first
isolated in 1971 [7], 23 years after the first clinical description of PML, and has since been found
to infect up to 90% of the global population [8]. The transmission of this virus is thought to
occur via the peroral route during childhood and adolescence, with approximately 65% of the
population infected by the age of 10 [9-11]. A key similarity among the human disease-causing
polyomaviruses, including JCPyV, is that the initial infection, in healthy individuals, results in an
asymptomatic infection that persists for the lifetime of the host [2, 12]. In the case of JCPyV,
the site of this persistence is the kidney, where it is thought that healthy immune function
ensures that the virus propagates at low levels without spreading to different tissues [13, 14].
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Figure 1. PML Pathogenesis. MRI of PML plaques (indicated by arrows) within the brain
of a 70-year old patient. [15] (Figure adapted with permissions form Journal of
NeuroVirology).
Upon severe immune system disruption, the virus is able to spread from the kidneys to
the central nervous system (CNS) where it shifts from a persistent, asymptomatic infection to a
highly lytic, pathogenic infection of oligodendrocytes and astrocytes. While the exact
mechanism of this lifecycle shift is not fully understood, it appears that changes within a
regulatory region of the viral genome is partially responsible [16-18]. In addition to cells of the
kidney and CNS, other cells types have been proposed as essential for the viral migration and
the development and progression of PML. B-cells have been suggested as a potential vehicle for
JCPyV to cross the blood brain barrier (BBB) during such periods of immune suppression in a
“Trojan horse” like model, in which JCPyV non-productively infects B-cells, gains entrance to the
CNS via lymphocyte migration across the BBB, and then goes on to infect glial cells [19].
Additionally, research utilizing a humanized mice model suggests a specific and active role
played by astrocytes in JCPyV infection of the brain. Astrocytes, which are readily infected by
the virus, are also capable of supporting a highly productive infection, thereby giving the virus a
2

sort of ‘jumping off point’ within the CNS prior to oligodendrocyte infection, destruction, and
neural demyelination [20].
The described migration of the virus from renal to glial sites of infection is seen most
commonly in patients infected with the human immunodeficiency virus (HIV) or those
undergoing prolonged immunomodulatory treatments for organ transplants, cancer, or any
number of autoimmune diseases, most notably, multiple sclerosis (MS) patients treated with
natalizumab, a monoclonal antibody against α4 integrins [3, 8, 21-23]. The onset of PML
requires, at the very least, that JCPyV be able to access the CNS and that the host’s immune
response stays suppressed once this occurs. In the case of HIV infection, the HIV virions are able
to enter the CNS inside infected monocytes that cross the BBB [24-26]. HIV replication within
the CNS can then lead to disruption to the BBB, increasing its permeability [24, 25]. As immune
suppression is a hallmark of HIV infection [27], this increased permeability at the BBB may set
the stage for JCPyV to enter the CNS and begin the pathogenesis of PML. Similarly, in patients
suffering from MS, the progression of their disease state can lead to a disrupted and more
permeable BBB [28]. If these patients receive treatment with natalizumab, the neutralization of
α4 integrins on leukocytes by the drug prevents their migration into the CNS [29, 30]. While this
is the desired action of the drug, as overactive T leukocytes within the CNS leads to the
pathology of multiple sclerosis [29, 30], it also results in reduced immune surveillance of the
CNS [31]. Incidence of PML is approximately 4% in HIV patients and is an AIDS-defining illness
[32]. The incidence of natalizumab-treated patients suffering from MS is 1:1000 to 1:100,
although the incidence in this population is dependent on a number of factors, including the
length of natalizumab treatment and a clinical history of other immunomodulatory therapies
[33-35].
Unfortunately, at this time there are currently no specific clinical treatments for either
PML or JCPyV infection [3] and the primary course of action is to attempt to rescue immune
function, either through HAART treatment in HIV patients or to cease immunomodulatory
therapies, such as that of natalizumab. However, these courses of action have the potential to
induce immune reconstitution inflammatory syndrome (IRIS) [4, 36]. IRIS within the CNS can
exacerbate PML pathology and can even be fatal in some cases [37]. Thus, gaining a better
3

understanding of the basic biology of the virus and virus-host cell interactions is an essential
step in the search for effective antiviral therapies.
1.2. JCPyV Structure and Lifecycle
JCPyV is a nonenveloped virus with a proteinaceous capsid composed of three structural
proteins, with viral protein 1 (VP1) being the major component. VP1 forms pentamers on the
external surface of the capsid, and each VP1 pentamer interacts with either a VP2 or VP3
molecule on the internal face of the capsid [38, 39]. VP1 is also responsible for the interaction
with host cell α2,6-linked lactoseries tetrasaccharide c (LSTc), which is required for viral
attachment [40]. The viral double stranded DNA genome (Figure 2) is approximately 5.1 kb in
length and contains the genes for viral products, the multifunctional large and small T antigens,
expressed early during infection and the later expressed agnoprotein and structural proteins,
VP1, VP2, and VP3 [3, 41]. Additionally, the genome contains a regulatory region with an origin
of replication and appears to play a significant role in maintaining the persistent infection
observed in the kidney. This region is also the site of a DNA rearrangement that appears to
result in the viral lifecycle shift that allows JCPyV to migrate to the CNS as described above [17].
Following viral attachment to the host cell, JCPyV gains entry to the cell via clathrinmediated endocytosis utilizing the serotonin receptor 5-hydroxytryptamine (5-HT) receptor,
specifically the type 2 receptors (5-HT2R), subtypes A, B, and C [42-44]. A schematic of JCPyV
attachment, entry, and trafficking is depicted in Figure 3. The virus traffics through the
endocytic compartment to the endoplasmic reticulum (ER) where it undergoes enzymemediated uncoating of the capsid [45]. The retrograde trafficking of JCPyV from the early
endosome to the ER is accomplished by way of transfer to caveolin-1 vesicles in a Rab5dependent manner [46]. This model for trafficking of JCPyV can be disrupted through the use of
small molecule inhibitors, preventing the virus from establishing a productive infection. One
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such inhibitor, Retro-2, forms a cyclic compound that interacts with yet undetermined host cell
factors, preventing this trafficking pathway and stopping JCPyV infection from progressing [47].

Figure 2. Schematic of JCPyV Genome. ‘Early’ genes on the left include large and small T
antigen while ‘Late’ genes on the left include the 3 structural proteins, VP1, 2, and 3, as
well as agnoprotein. Viral early and late genes are separated by a non-coding control
region which contains the origin of replication and serves in a regulatory capacity [41].
(Figure adapted from PLoS One under Creative Commons licenses).
JCPyV then gains entry to the nucleus through nuclear localization signals revealed by
uncoating. Following this, the early gene, large T antigen, is expressed through cellular
transcription [3, 8]. T antigen regulates the host cell cycle via interaction with the tumor
suppressor p53, driving the cell into S-phase for viral genome replication and expression of the
late gene products that are required for viral capsid assembly [8]. The multi-functionality of
viral T antigen allows it to coordinate and direct a number of steps required for late gene
expression and direct control of the host cell cycle. T antigen is able to bind the regulatory
region of the JCPyV genome, act as a helicase, and recruit host cell replication machinery
(including polymerase) in order to drive viral genome replication. It also binds p53 and
retinoblastoma (pRB) proteins, modulating their control of the cell cycle and usurping pRB
recruitment of transcription factors to aid in the transcription and subsequent expression of
viral late genes [23].

5

Figure 3. JCPyV Infectious Cycle. Viral attachment and entry requires both α2,6-LSTc and
5-HT2R before proceeding through clathrin-mediated endocytosis. The virus then
undergoes retrograde transport via a caveolin-1 vesicle to the ER, undergoing enzymemediated uncoating in the process. Once internalized the virus traffics to the nucleus for
transcription and replication to occur [48] (Figure adapted with permissions form
Journal of NeuroVirology).
1.3. Cellular Signaling Pathways in JCPyV Infection
Work published from the Maginnis lab in recent years has illustrated the role of the
mitogen-activated protein (MAP) kinase cascade during JCPyV infection. In this model, JCPyV
has been shown to activate MAP kinase signaling leading to phosphorylation of extracellular
signal-regulated kinase (ERK) and subsequent phosphorylation of proteins needed for
productive JCPyV infection as well as nuclear translocation of transcription factors thought to
promote viral gene expression and replication [49, 50].
A number of chemical inhibitors of different kinases within this signaling cascade have
been shown to inhibit productive JCPyV infection. These include PD98059 and U0126, inhibitors
of MAP kinase kinase (MEK) 1 and 2, which prevent activation of the critical MAPK-ERK pathway
and productive JCPyV infection [50]. Knockdown of an additional upstream activator of this
6

pathway, Rapidly Accelerated Fibrosarcoma kinase (RAF), has also been shown to prevent
JCPyV infection [50]. BAY 43-9006, a drug that inhibits RAF [51], has similarly been shown to act
as an inhibitor of JCPyV infection [52].
Currently unpublished work from the Maginnis lab has also suggested a critical role for
calcium ion signaling in the infectious cycle of JCPyV. These experiments have illustrated a
potential dependence by the virus on calcium signaling from the ER of an infected cell following
endocytosis. Such calcium signaling is known to play a role in the lifecycle of other viruses
during multiple steps of infection [53]. There is also evidence that a viral protein encoded by the
JCPyV genome, agnoprotein, plays a role as a viroporin that increases the permeability of
cellular membranes to calcium ions [54]. The preliminary model for the role of calcium is
illustrated in Figure 4. In this model, JCPyV activation of the 5-HT2R leads to activation of
phospholipase C (PLC), subsequent cleavage of Phosphatidylinositol 4,5-bisphosphate (PIP2) to
diacylglycerol (DAG) and inositol triphosphate (IP3). This leads to the activation of the IP3
receptor at the ER membrane and release of calcium ions into the cytosol, where it triggers a
number of signaling mechanisms, including the translocation of Nuclear factor of activated Tcells (NFAT) to the nucleus as a result of activated calmodulin-dependent kinase [55]. Nuclear
translocation of NFAT then drives the transcription of genes beneficial to the viral lifecycle [56].
While this exact signaling mechanism has not been definitively shown to occur during JCPyV
infection, it is an area of on-going research.
Many aspects of JC polyomavirus infection, including gaps in our understanding of how
the virus is reactivated during states of persistence and becomes pathogenic, are not fully
understood [23, 57]. Combined with a lack of effective treatments for PML [3], the need for
further research is evident. There are no tractable animal models of JCPyV infection and PML
pathogenesis, and the development of animal models is in part limited due to the restricted
viral host range, a limitation in the study of most polyomaviruses [2, 58]. Furthermore, rather
than the disease progression seen in infected immunocompromised humans, JCPyV infection in
animals leads to tumorigenesis due to production of large T antigen, an oncogene [59].
Although this may change in the future as work with a humanized mice model is explored [20,
60], this model is not currently widely used, nor is it without its own limitations and obstacles.
7

These limitations restrict research of JCPyV and PML pathogenesis to human cell culture
models. JCPyV infection is only permissive in a limited number of tissues, specifically the
kidneys and CNS, due to the requirement of JCPyV to interact with both α2,6-LSTc and 5-HT2Rs
for attachment and entry, further limiting how researchers can conduct experimental
investigations of productive JCPyV infection [23, 43, 61].

Figure 4. A Potential Role for Calcium Signaling in the JCPyV Infectious Lifecycle.
Preliminary model for the activation of calcium release from the ER due to JCPyV
activation of the 5-HT2R and subsequent translocation of a transcriptional factor to the
nucleus, spurring the expression of genes beneficial to the replication of the virus [62].
1.4. Experimental Methods of Viral Infectivity
Viral infectivity is typically quantified via assays such as the plaque forming assay and
the focus forming unit (FFU) assay. The plaque assay relies on a virus infecting the cells of a
monolayer and causing them to lyse, forming visible plaques that are easily quantified. Nonplaque forming viruses (such as JCPyV) cannot be analyzed using this method [63], leaving the
FFU as one of the only reliable methods of quantifying JC polyomavirus infectivity [43]. The FFU
procedure relies on indirect immunodetection staining and epifluorescence microscopy to
visualize viral infectivity [39, 52]. Infected cells are stained using an antibody that recognizes a
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viral protein, such as VP1 in the case of JCPyV. Cells are subsequently stained with a
fluorescently-conjugated antibody. Fluorescence staining represents an infected cell, and the
percentage of infected cells in a population can be quantified manually using an
epifluorescence microscope. While this technique has been incredibly useful in JCPyV research,
this method of measuring viral infectivity also presents several obstacles. The FFU introduces
observer bias, relies on partial analysis of samples to generate representative data, and
requires a large amount of time for data generation, reducing the productivity of JCPyV
research and preventing high-throughput experimentation.
A relatively new technique, known as the In-cell Western assay (ICW), has been
developed as a high-throughput method for visualizing protein expression within cells [64] and
has been adapted by the field of virology for use in determining relative viral protein expression
as a method of quantifying viral infectivity for influenza A and herpes simplex virus-1 [65, 66].
This high-throughput platform has also been used to successfully measure the effects of
neutralizing antibodies, molecular inhibitors and antiviral molecules on the in vitro replication
of Hantaan virus, as well as reovirus and rotavirus, and, more recently, JCPyV in the Maginnis
lab [52, 65, 67, 68]. Moreover, the utility of the assay has been increased through its use in
monitoring host protein expression as a result of viral infection [52, 69].
In contrast to the FFU, the ICW assay relies on indirect immunofluorescence detection
via an automated infrared imaging system, the LI-COR Odyssey CLx. As with other indirect
immunofluorescence detection techniques, cellular proteins are detected through the
application of a protein-specific primary antibody and complementary secondary antibody
conjugated to a fluorescent tag. The ICW technique employs the utilization of a near infrared
(NIR) fluorescent secondary antibody, which allows for scanning of an entire sample plate via
the LI-COR Odyssey CLx. The same sample preparation described for the FFU assay is used for
this method of infectivity determination with the exception that the staining reagents used are
conjugated to the NIR tags described, allowing for the use of an infrared imaging device.
Because this device is automated, quantified data of viral infection is obtained much more
rapidly than when measured via FFU. This saves, potentially, hours of data collection per
experiment and allows for types of experimentation that are much larger in scope. This
9

functional advantage of the ICW, over the FFU, has the potential to greatly increase the rate of
discovery in JCPyV research, particularly in the context of identifying antiviral agents for further
development. A comparison of the FFU and ICW methods of quantifying viral infection is
demonstrated in Figure 5. Although the use of this assay as an analytic tool across a number of
different viral species is growing, the ICW requires validation before work with new viruses can
begin.

A
DuShane et al. Front. Microbiol, 2019.

B

C

Figure 5. ICW vs FFU in Quantifying JCPyV Infection. A) SVG-A cells stained for FFU
analysis (left) and SVG-A cells stained for ICW (right). B) Schematic of glial cells stained
for FFU, nuclei have been stained with DAPI (blue). Immunostaining of JCPyV with green
fluorescent antibody signals presence of VP1 expression within cellular nuclei.
Performing a quotient of the number of VP1 positive nuclei and the number of DAPI
stained nuclei yields a “percent infection.” C) Schematic of glial cells stained for ICW, cell
cytoplasm have been stained with nonspecific CellTag™ 700 (LI-COR) (red).
Immunostaining of JCPyV with near infrared-green antibody signals presence of VP1
expression within cells. Performing a quotient of the near infrared intensity of the green
signal and the near infrared intensity of the red signal yields a “percent response.”
(Images adapted from Frontiers in Microbiology under Creative Commons licenses,
virion models adapted with permissions from Nature) (Created with BioRender).
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1.5. Reovirus Background
In order to develop a novel ICW assay for measuring JCPyV infection, reovirus was
selected as a model for the development of this assay with JCPyV-specific cell culture
parameters. Reovirus is a nonenveloped dsRNA virus that infects many host species, including
humans. While not typically implicated in human disease, it is a widely studied model of
molecular virology and viral pathogenesis [70, 71]. The reovirus capsid has protruding
filamentous proteins (σ1) that interact with host cell glycans and junctional adhesion moleculeA (JAM-A) to attach to the extracellular face of the cell. Reovirus is then thought to enter the
host cell through interaction with β1 integrins [72]. Following entry, reovirus undergoes an
enzyme-mediated uncoating process within lysosomes before being released into the cytosol
where viral RNA dependent RNA polymerase, carried within the capsid, begins the transcription
of the viral genome segments leading to viral replication and protein expression [73]. Figure 6
provides a general overview of the reovirus infectious lifecycle.

Figure 6. Reovirus Internalization. Reovirus capsid proteins adhere to host cells through
interaction with cell surface sialic acid and JAM-A and gain entry to the cell via β1
integrins. Once uncoated the virus begins genome transcription and protein expression
in the cytosol [70, 74]. (Figure adapted from Viruses under Creative Commons licenses).
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CHAPTER 2
MATERIALS AND METHODS
2.1. Cell Culture
SVG-A cells, a mixed population of human fetal glial cells mainly composed of astrocytes
[75], were maintained in Eagle’s minimal essential medium (10% FBS, 1%
penicillin/streptomycin, 0.2 % plasmocin) (c-MEM). Human embryonic kidney (HEK293A) cells
(ATCC) expressing 5-HT2AR were maintained in Dulbecco’s modified Eagle’s medium (10% FBS,
1% penicillin /streptomycin, 0.2% plasmocin) (c-DMEM) [43]. Cell lines were grown in a
humidified incubator at 37C with 5% CO2. Cells were subcultured upon 90-100% confluency by
passaging cells in fresh medium at a frequency of at least once every six days. Cell lines were
kindly provided by Dr. Walter Atwood’s laboratory (Brown University).
2.2. Reovirus Infectivity Assay
SVG-A and HEK293A cells were plated in 96-well plates (7,000 cells/well) and incubated
at 37C with 5% CO2 until the cell monolayer reached ~70% confluency. Cells were infected with
reovirus T1L strain inoculum (MOI indicated as per figure legend) in a total volume of 50 μL of
complete media (lacking plasmocin) per well and incubated at 37C for 1 h. Complete media
was added back to appropriate wells (50 μL) and incubated at 37C for 24 h. At 24 hours post
infection (hpi), cells were fixed in 4% paraformaldehyde (PFA) at RT for 10 mins, washed once in
sterile 1XPBS, and stored at 4C until analysis.
2.3. JCPyV Infectivity Assay
SVG-A cells were plated in 96-well plates (7,000 cells/well) and incubated at 37C until
monolayer reached ~70% confluency. Cells were infected with JCPyV viral inoculum (MOI
indicated per figure) in c-MEM (lacking plasmocin) in a total volume of 50 μL per well and
incubated at 37C for 1 h. Complete media (without plasmocin) was added back to appropriate
wells (50 μL) and incubated at 37C for 72 h. At 72 hpi, cells were fixed in 4% paraformaldehyde
(PFA) at RT for 10 mins, washed once in sterile 1XPBS, and stored at 4C until analysis.
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2.4. Focus Forming Unit (FFU) Assay
2.4.1. Reovirus
Fixed cells were permeabilized in 1XPBS with 1.0% Triton X-100 at RT for 15 mins with
gentle shaking. Cells were blocked with LI-COR Odyssey blocking buffer (TBS or PBS) at RT for
1.5 h with gentle rocking. Infected cells were stained with a rabbit derived T1L/T3D reovirus
antisera (generously provided by Pranav Danthi, Indiana University) (1:5000) in LI-COR Odyssey
TBS/PBS blocking buffer. Cells were incubated at 4C O/N with gentle rocking. Samples were
washed 3X with 0.1% Tween-TBS at RT for 10 mins with gentle rocking prior to being stained
with a secondary antibody, anti-rabbit Alexa488 (Invitrogen [a11070]) (1:1000) in LI-COR
Odyssey blocking buffer (TBS or PBS) at RT for 1 h with gentle rocking while protected from
light. Cells were washed 3X with 0.1% Tween-TBS at RT for 10 mins with gentle rocking. Cell
nuclei were stained with DAPI (1:1000) in 1XPBS at RT for 5 mins and then washed 3X with 0.1%
Tween-TBS at RT for 10 mins with gentle rocking. Samples were analyzed via a Nikon Eclipse Ti
epifluorescence microscope (Micro Video Instruments, Inc.) using Nikon NIS-Elements Basic
Research software (version 4.5). Total cell counts were determined using a binary to identify
DAPI-stained nuclei, and infected cell counts were determined manually in 5 fields of view,
percent infection determined by a quotient of reovirus-positive cells and DAPI cells in each field
of view and averaged for each well. Each viral MOI was analyzed in at least three wells. Samples
were viewed at 10X magnification.
2.4.2. JCPyV
Fixed cells were permeabilized in 1XPBS with 1% Triton X-100 at RT for 15 mins with
gentle shaking. Cells were blocked with LI-COR Odyssey blocking buffer (TBS or PBS) at RT for
1.5 h with gentle rocking. Infected cells were stained with a JCPyV VP1-specific antibody
(Abcam [ab34756]) (1:1000) in LI-COR Odyssey TBS/PBS blocking buffer. Samples were
incubated O/N at 4C with gentle rocking then washed 3X with 0.1% Tween-TBS at RT for 10
mins with gentle rocking prior to being stained with a secondary antibody, Alexa488 (Invitrogen
[a11017]) (1:1000) in LI-COR Odyssey blocking buffer (TBS or PBS) at RT for 1 h with gentle
rocking while protected from light then washed 3X with 0.1% Tween-TBS at RT for 10 mins with
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gentle rocking. Cell nuclei were stained with DAPI (1:1000) in 1XPBS at RT for 5 mins and
washed 3X with 0.1% Tween-TBS at RT for 10 mins with gentle rocking. Samples were analyzed
via epifluorescence microscopy. Total cell counts and infected cell counts were determined in 5
fields of view and averaged for each well, and percent infection was determined by a quotient
of VP1-positive cells and DAPI-positive cells. Each viral MOI was analyzed in 3 wells. Samples
were viewed at 20X magnification as described above.
2.5. In-Cell Western (ICW) Assay
Fixed cells were permeabilized in 1XPBS with 1.0% Triton X-100 at RT for 15 mins with
gentle rocking. Cells were blocked with LI-COR Odyssey blocking buffer (TBS or PBS) at RT for
1.5 h with gentle rocking. Infected cells were stained with a rabbit derived T1L/T3D reovirus
antisera (1:5000) in LI-COR Odyssey TBS/PBS blocking buffer or JCPyV VP1-specific antibody
(Abcam [ab34756]) (1:1000) in LI-COR Odyssey TBS/PBS blocking buffer. Cells were incubated
O/N at 4C with gentle rocking. Samples were washed 3X with 0.1% Tween-TBS at RT for 10
mins with gentle rocking prior to being secondarily stained with a LI-COR antibody (680)
conjugated with an IR fluorophore ([926-32210] (1:10,000)) in LI-COR Odyssey blocking buffer
(TBS or PBS) and a LI-COR IR CellTag™ 700 ([926-41090] (1:500)) and incubated at RT for 1 h
with gentle rocking. A sample of uninfected cells were treated with both antibodies and
another sample was treated with only the secondary antibody as controls. Cells were washed
3X with 0.1% Tween-TBS at RT for 10 mins with gentle rocking. Samples were analyzed via the
LI-COR Odyssey Automated IR Imager System with a focus offset of 3 mm and 700 and 800 nm
channel intensities settings of 5 at a resolution of 84 μm. Percent ICW response was
determined by a quotient of the intensity of the 800 channel and the intensity of the 700
channel.
2.6. Chemical Inhibitor Assay
SVG-A cells at 70% confluency were pretreated for 1 h (at 37C with 5% CO2) with 50 μL
of a molecular inhibitor prior to infection with JCPyV (MOI= 0.5 FFU/cell). Pretreatments were
removed prior to infection. At 1 hpi, inhibitors were added back in the media feed. Of the four
inhibitors used, PD98059 (2′-amino-3′-methoxyflavone), U0126 (1,4-diamino-2,3-dicyano-1,414

bis[2-aminophenylthio] butadiene), and Retro-2 (2-{[(5-methyl-2-thienyl)methylene]amino}-Nphenylbenzamide) were present in the media for the full 72 h incubation period at 37C. Bay439006 (4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy) N-methylpicolinamide 4methylbenzenesulfonate ), was also added back in the media but was removed at 2 hpi and
replaced with untreated c-MEM for the full 72 h incubation period at 37C. Each inhibitor used
was compared to a vehicle control of DMSO. Experiment was analyzed via ICW.
2.7. NIH-CC Drug Screen
The National Institute of Health’s Clinical Collection (NIH-CC) (kindly provided by the
Mainou laboratory, Emory University), a library of 700 drugs and small molecules, was received
frozen in solution with DMSO at a concentration of 1 mM. All drugs were stored in 96-well
plates, with 80 drugs per plate across 9 plates. For each drug in the library, a 1:100 dilution was
performed. Diluted drug samples (50 μL) were applied to SVG-A cells at 70% confluency for 1 h,
1 well per drug and incubated at 37C. JCPyV (MOI= 0.5 FFU/cell, 30 μL) was added to every
well while retaining the pretreated media in each well. At 1 hpi, 30 μL of c-MEM was added
back to each well. Each experimental plate of 80 drugs also contained the controls: 4 wells of
mock infected cells (receiving no virus), 4 wells of vehicle control DMSO for the drugs in the
screen, 4 wells of PD98059 (50 μM) (positive control for viral inhibition), and 4 wells of vehicle
control DMSO for the PD98059 control. Experiments were analyzed via ICW.
2.8. Validation of Topiramate
SVG-A cells at 70% confluency were pretreated for 1 h with various concentrations of
topiramate at 37C. This pretreatment was aspirated and the cells were infected for 1 h with
JCPyV at a MOI of 1 (FFU/cell) at 37C, in media containing topiramate at the same
concentration as the pretreatment. Cells were fed with media containing topiramate and
incubated at 37C for 72 h fixed, stained for VP1, and processed for analysis by FFU. A vehicle
control treated sample was included under the same conditions.
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2.9. Statistical Methods
Statistical and computational analysis was conducted in Microsoft Excel. Statistical
differences in both percent response and percent infection measurements were determined via
the Student’s t test. Z-score analysis of drugs from the NIH-CC was conducted as follows: an
inhibitory effect against JCPyV for each drug in the screen was calculated by subtracting the
percent ICW response of the negative control from the percent ICW response for each drug.
The z-score of each inhibitory effect was calculated by subtracting the average inhibitory effect
of all drugs within a single cell culture plate, divided by the standard deviation of the negative
control for that plate, from the inhibitory effect of a given drug. Each z-score was compared to
a ‘hit’ threshold that required it be lower than the negative value of the number of drugs on the
same plate multiplied by the standard deviation inhibitory effect of those drugs. Statistical
analysis performed in Microsoft Excel.
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CHAPTER 3
RESULTS
3.1. Adaptation of the ICW for use in JCPyV Permissive Cell Models
The lack of a high-throughput platform for analysis of JCPyV infectivity has slowed
research efforts and hampered the search for antiviral therapeutics for PML. The traditional
FFU methodology for assessing viral infectivity is a reliable technique, albeit one that requires a
large investment of time and person-hours to generate infectivity data. Adaptation of the
newer ICW technique for use in JCPyV studies would provide researchers with an extremely
high-throughput tool, allowing for larger scale experimentation. In contrast to the FFU assay,
the ICW assay relies on indirect immunofluorescence detection via an automated infrared
imaging system, the LI-COR Odyssey CLx. As with other indirect immunofluorescence detection
techniques, cellular proteins are detected through the application of a protein-specific primary
antibody and complementary secondary antibody conjugated to a fluorescent tag. The ICW
technique employs the utilization of a near infrared (NIR) fluorescent secondary antibody,
which allows for scanning of an entire sample plate via the LI-COR Odyssey CLx.
Published work by Iskarpatyoti et al. has shown that the ICW assay is a valid method of
measuring relative differences in the in vitro infectivity of reovirus, a traditional model for
laboratory analysis of viral pathogenesis [67, 71] in cell types pertinent to typical reovirus
studies. In order to establish the ICW as a viable method for measuring JCPyV infection, we
began by bridging the established use of the ICW with reovirus to viral infectivity studies in cell
models permissive to JCPyV, SVG-A and HEK293A cells. To address this, the correlation between
FFU and ICW determinations of reovirus infectivity in these cell types was investigated (Figure
7).
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Figure 7. ICW Determination of Reovirus Infectivity. A) HEK293A (left) and SVG-A cells
(right) infected with T1L strain reovirus at MOIs (FFU/cell) indicated were incubated for
24 h. Cells were then fixed and stained using ICW techniques and quantified via the
automated LI-COR Odyssey CLx infrared imager. B) ICW infectivity data was collected at
the viral MOIs indicated. Relative intensity values are expressed as percent response of
the highest viral MOI used. Error bars represent SD from 3 replicates. C) Data from ICW
experiments was compared to identical condition FFU infectivity assays. These samples
were stained for viral protein expression and quantified as percent infection via
epifluorescence microscopy. Microscopy data represents the average percentage of
infected cells (total cell counts determined by DAPI staining) in five fields of view per
well, performed in three replicates per viral MOI. Raw FFU data not shown. Linear
correlation between assays was determined with a Pearson correlation coefficient test.
Experiments shown are representatives of experiments performed in triplicate.
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Both SVG-A and HEK293A cells were infected with reovirus at viral MOIs between 10
and 0.078 (FFU/cell), processed for ICW analysis, and imaged via the LI-COR Odyssey CLx (Figure
7A). The percent response to ICW analysis in both cell types was quantified and normalized to
the highest level of reovirus infection (Figure 7B). The level of infection signified by this percent
response was observed to correlate with viral MOI.
Comparison of this percent ICW response data to percent infection data from
experiments completed in parallel, processed and imaged for FFU analysis, showed a high
degree of correlation, as measured by Pearson correlation coefficients in both cell models
approaching a value of 1 (Figure 7C). These experiments show that the ICW assay is useful for
making relative determinations of reovirus infectivity in both SVG-A and HEK293A cell culture
models.
3.2. The ICW Assay as a Method of Quantifying JCPyV Infection
Full validation of the ICW platform for adaptation to JCPyV studies required the first
ever analysis of JCPyV infectivity with this new tool. To establish the viability of the ICW as a
tool for measuring the infectivity of JCPyV in vitro, a similar investigation to that described
above was completed to correlate the infectivity of JCPyV in SVG-A cells as determined by ICW
and FFU methodologies. SVG-A cells were infected with JCPyV at viral MOIs between 2 and
0.0157 (FFU/cell), processed for ICW analysis, and imaged via the LI-COR Odyssey CLx. The
percent response to ICW analysis was quantified and normalized to the highest level of JCPyV
infection (Figure 8A). Comparison of this percent ICW response data to percent infection data
from an experiment completed in parallel, processed and imaged for FFU analysis, showed a
high degree of correlation, as measured by a Pearson correlation coefficient approaching a
value of 1 (Figure 8B). Data are representative of independent experiments performed at
varying MOIs [52].
ICW analysis of JCPyV in SVG-A cells demonstrates that the technique is a viable tool for
assessing relative differences in viral infection. However, before this tool can be fully adapted
for laboratory use in JCPyV studies, its utility in a functional assay must be examined.
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Figure 8: ICW Determination of JCPyV Infectivity. A) SVG-A cells infected with JCPyV at
varying MOIs (FFU/cell) were incubated for 72 h. Cells were then fixed and stained for
viral protein expression with an IR fluorescent dye before being quantified via the
automated LI-COR Odyssey CLx infrared imager. Relative intensity values are expressed
as percent response of the highest viral MOI used. Error bars represent SD from three
replicates. B) Indirect immunofluorescence microscopy of samples infected under
identical conditions was also performed. Microscopy data (not shown) represents the
average percentage of infected cells in five fields of view (20X) per well, performed in
triplicate per viral MOI. Linear correlation between assays was determined by a Pearson
correlation test. Data are representative of independent experiments performed at
varying MOIs [52].
3.3. Viral Inhibitor Efficacy as Assessed by ICW
The ICW was established as a method to perform large-scale screens to accelerate the
pace of JCPyV research. Prior to performing the proposed drug screen with the NIH-CC, it was
necessary to establish the utility of the ICW as an effective tool to test potential antivirals. To
this end, SVG-A cells were treated with chemical inhibitors that were previously demonstrated
to reduce JCPyV infection. Cells were pretreated with one of four chemical inhibitors (Figure 9),
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then infected with JCPyV, and infection was measured by ICW analysis. For all inhibitors tested,
a statistically significant reduction in JCPyV infection was observed via ICW analysis. Chemical
inhibitors of MEK, PD98059 and U0126 [50], reduced JCPyV infection by approximately 54% and
35%, respectively, in comparison to the vehicle control for each chemical (Figure 9A and 9B).
The other chemicals tested, Bay43-9006, an inhibitor of b-Raf [50], reduced JCPyV infectivity by
approximately 62%, and Retro-2, an inhibitor of retrograde trafficking, reduced infectivity by
approximately 27%, relative to the vehicle control (Figure 9C and 9D). These experiments, taken
together, are a strong positive indicator that the ICW assay can be relied upon as an accurate
tool in determining the relative level of JCPyV infection in vitro under various circumstances.
This finding, in conjunction with the high-throughput capacity of the LI-COR Odyssey CLx, opens
the door to large scale screening experiments that are currently infeasible given the time
investment required to accomplish them by FFU analysis.
3.4. Large Scale Drug Screen of NIH-CC via ICW
Following the development of the ICW assay as a valid and effective tool for visualizing
and quantifying relative difference in JCPyV infectivity in SVG-A cells [52], it was then adapted
for the high-throughput utility of the assay in a large-scale drug screen. The NIH-CC was
obtained through a collaboration with the Mainou laboratory (Emory University). This library
contains 700 drugs and other small molecules (listed in full in Appendix A) that have been used
in clinical trials in humans. This library was then screened against JCPyV and analyzed via ICW in
three independent experiments. As described above, the effect of each of these 700 drugs and
small compounds on the ability of JCPyV to infect SVG-A cells was then assessed as a z-score.
Of the 700 compounds assessed in these experiments, 42 were determined to meet the
above described criteria to be considered as anti-JCPyV candidates under the conditions tested.
As each plate was imaged independently via the LI-COR Odyssey CLx, the z-score threshold for
each plate is independent of the others. The z-scores of every drug in each replicate were
normalized to their respective z-score threshold and plotted in Figure 10A. In this
normalization, any replicate with a z-score of less than −1 (Figure 10B) was considered to have
crossed the threshold.
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Figure 9. ICW Determination of Viral Inhibitor Efficacy. SVG-A cells were pre-treated
with either the inhibitor indicated or a volume specific control of DMSO. Cells were then
infected with JCPyV (MOI=0.5 FFU/cell) for 1 h. A) PD98059 (50 μM) an inhibitor of MEK.
B) U0126 (10 μM) an inhibitor of MEK. C) Bay43-9006 (15 μM) an inhibitor of b-Raf. D)
Retro-2 (100 μM) an inhibitor of retrograde trafficking. Following a 1 h infection, treated
media was added back to wells; for PD98059, U0126, and Retro-2, the treated media
remained on the cells for 72 h. For samples treated with media containing Bay43-9006,
this media was removed 2 hpi and replaced with untreated media for the remainder of
the 72 h. Cells were fixed and stained for viral protein expression with an IR fluorescent
dye before being quantified via the automated LI-COR Odyssey CLx infrared imager
(ICW). Error bars represent SD from six samples. *, P<0.05, **, P<0.01.
Compounds were determined to be an antiviral candidate if they crossed this z-score
threshold in at least 2 of the 3 independent experiments. A literature review of the main
mechanism of action, or function, of each of these candidate drugs returned a wide variety of
results (Appendix B) and was used to group all 42 candidate drugs by function (Figure 10C).
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Figure 10. Identifying Antiviral Drugs from the NIH-CC. 700 individual drugs and small
molecules were assessed for antiviral activity in a high-throughput screen against JCPyV
in SVG-A cells. Cells were treated with media containing 10 μM concentrations of each
drug or small molecule for 1 h then infected with JCPyV (MOI = 0.5 FFU/cell) for 1 h.
Infected cells were then fed, incubated at 37˚C for 72 h, stained for VP1, and processed
for ICW analysis. The statistical significance (z-score) of the effect of each drug on JCPyV
infectivity was scored as described. z-scores were normalized to the z-score threshold
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for the plate containing any particular drug. A) Plot of the normalized z-score of every
drug in each replicate. B) All replicates with a normalized z-score that crossed the zscore threshold. Point color indicates which replicate each z-score belongs to; Orange
represents replicate 1, Green represents replicate 2, Blue represents replicate 3. Drugs
with z-scores crossing the normalized threshold of -1 in 2 of 3 replicates were
considered candidate antivirals. C) Candidate drugs grouped by functionality.
3.5. Validating an Antiviral Compound
Having narrowed the library of 700 drugs and compounds down to 42 anti-JCPyV
candidates, validation of the results of the drug screen in a targeted manner was then
performed in order to identify anti-JCPyV candidates for further characterization. Topiramate, a
drug sorted into the functional group containing inhibitors of calcium ion signaling (Appendix
B), was applied to SVG-A cells at concentrations between 10 μM and 200 μM and tested against
JCPyV infection at an MOI of 1 FFU/cell (Figure 11). In this experiment, concentrations of
topiramate above 50 μM reduced JCPyV infectivity by approximately 30 to 40% when compared
to the vehicle control. However, a dose response was not observed. The levels of JCPyV
infection in cells treated with 50, 100, and 200 μM topiramate were not significantly different.
The data shown here is representative of experiments performed in duplicate.
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Figure 11. Effect of Topiramate on JCPyV Infection. SVG-A cells were treated for 1 h
with the indicated concentration of the drug topiramate prior to infection with JCPyV at
a MOI of 1 FFU/cell for 1 h. Infections were carried out in the presence of topiramate.
Cells were then fixed at 72 hpi and stained for viral protein expression with a fluorescent
tag before being quantified via FFU. Error bars represent SD from 3 samples. **, P<0.05.
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CHAPTER 4
DISCUSSION AND FUTURE DIRECTIONS
Clinical treatment of PML is limited to attempts to rescue the underlying immune
suppression that precipitated the disease onset, typically through the initiation of HAART
treatment or the discontinuation of immunomodulatory therapies. However, these courses of
action are not without their own risks, as reactivation of the immune system can result in
induction of IRIS within the CNS [4, 36], with potentially disastrous or even fatal results [37].
While some antiviral therapies have been approved on a compassionate use basis, such as
pembrolizumab [76], but these case-by-case treatments do not represent a realistic path
forward for effective or scalable treatment development. The debilitating and often fatal
outcomes associated with PML, paired with the lack of specific, approved clinical treatments,
makes the identification and development of antiviral therapeutics a critical area of research.
However, to date, laboratory research into the etiologic agent of this disease, JCPyV, has
suffered from the lack of a high-throughput methodologies, hampering the progress of studies
in this area. The lack of such tools was the catalyst for the work presented here. To this end, we
have established the ICW assay as an effective tool for high-throughput JCPyV infectivity
studies.
The experiments presented here, illustrate the utility of the ICW assay to make accurate
determinations of relative differences in the infectivity of JCPyV in the SVG-A cell culture model,
on par with traditional methodologies. We have expanded the use of this assay to visualize
reductions in JCPyV infection due to chemical inhibitors of host cell processes usurped by the
virus during productive infections. With these base requirements of laboratory utility and the
capacity of this technique to reduce person-hours and overall time investment in the
quantification of infectivity experiments by at least 8 hours per experiment, we have
successfully adapted the ICW assay as a new high-throughput platform for JCPyV studies. It has
not been previously feasible, without the use of highly-specialized equipment, to carry out this
type of large-scale experimentation. The demonstrated potential of this assay to function in a
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high-throughput capacity will greatly increase the rate of discovery in JCPyV research, aiding in
the search for potential antiviral therapeutics, as well as that for other viral pathogens.
Our investigation of the high-throughput capability of this assay, the first large-scale
screening of a drug library for antiviral agents against JCPyV analyzed by ICW, has yielded a
wealth of interesting and suggestive results. These experiments have identified drugs and
compounds with the potential to reduce JCPyV infectivity in vitro. While more work is necessary
to validate these results, the identification of a number of drugs, whose mechanisms of action
impact cellular pathways, known or expected to play critical roles in the JCPyV infectious cycle,
reinforces confidence that these results may yet bear fruit in the search for therapeutics against
JCPyV.
As many of the drugs within the NIH-CC library are currently FDA approved and on
market, the possibility of observing antiviral activity against JCPyV by a drug already approved
for clinical use was a distinct possibility. In fact, a previously performed drug screen of a
different library of compounds by Brickelmaier et al. against JCPyV (in which a decidedly less
high-throughput technique was employed) identified an on market antimalarial, mefloquine, as
potentially having anti-JCPyV activity. In this work, they hypothesized this activity could be a
result of the spatial similarity of mefloquine with nucleoside analogues, potentially allowing it
to disrupt virus-specific genome replication via direct interaction with viral T antigen [77].
Mefloquine is a member of a drug class known as the quinoline-containing antimalarial drugs
[78], and although the exact mechanism of action of mefloquine is not clear, other members of
this drug class are more well studied. Their function may provide insight into that of
mefloquine.
Perhaps the most well studied drug in this class, chloroquine, has been known for its
immunomodulatory activity for some time. More recently, its potential antiviral properties have
been an active area of research [79-82]. The primary mechanism of chloroquine is thought to
be its activity as a base, raising the pH of endosomes and lysosomes considerably, disrupting
their function. This activity modulates immune function by preventing the function of Toll-like
receptors (TLR 7 and 9), reducing the production of cytokines and preventing nuclear
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translocation of transcription factors that stimulate immune system associated genes [82]. The
antiviral properties associated with chloroquine are likely a result, at least in part, of these
activities but chloroquine and closely related analogues have also been shown to prevent HIV
and dengue virus infectivity in vitro by altering the pH of endosomes containing progeny virus
particles, preventing the proper formation and function of viral glycoproteins needed for
subsequent host cell infections [79, 81]. Additionally, chloroquine has been shown to inhibit the
ability of the hepatitis A virus to properly shed its capsid within acidic endosomes due to this
change in pH [83]. Chloroquine and its closely related analogues have also been implicated as
potential therapeutics for human coronaviruses [80] and are currently under investigation as
potential therapies for SARS-CoV-2, the causative agent of COVID-19.
Unfortunately, clinical studies of mefloquine efficacy against JCPyV in PML patients has
been inconclusive as of yet [84], however its use as an adjunct therapeutic has not been ruled
out. The treatment of PML patients with mefloquine in conjunction with the drug mirtazapine,
an antagonist of 5-HT2ARs, which are required for JCPyV entry, has been studied to some with
some anecdotally positive clinical outcomes [85-87]. Although these case studies do not yet
represent conclusive proof of clinical efficacy, the rapid adoption of mefloquine treatment for
PML patients illustrates the great potential for high-throughput analysis to identify marketed
drugs with anti-JCPyV activity that can be explored in a clinical capacity, relatively quickly.
Of the 42 anti-JCPyV candidates identified here by ICW analysis, sixteen are known
agonists or antagonists of G-protein coupled receptors (GPCRs), several of which affect
serotonin receptor signaling of the 5-HT2R family utilized by JCPyV for host cell entry. Seven of
these candidate drugs are known to impact the release, cellular retention, and signaling of
calcium ions; processes known to impact the infectivity and lifecycle of many viruses, and for
which preliminary research has indicated an important role in the JCPyV lifecycle. Additionally,
2 of the candidate drugs fall within the class of nonsteroidal anti-inflammatory drugs (NSAIDs),
which have been previously suggested as a class of drugs capable of reducing JCPyV infection in
vitro [77]. NSAIDs have been implicated as antiviral therapeutics previously with a mechanism
similar to that offered by Bickelmaier et al., the selective inhibition of viral RNA synthesis of
coronaviruses and influenza viruses [88, 89].
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The GPCRs, 5-HT2Rs are critical receptors for JCPyV entry into host cells [42-44]. Also of
note, these receptors and chemical inhibitors of these receptors have been implicated in the
infectious lifecycle of other viruses, including reovirus [90, 91]. The discovery of multiple 5-HTR
targeting drugs via a screen of the NIH-CC against reovirus analyzed by ICW [90], implicated this
class of receptors in the reovirus lifecycle and further analysis of one of these compounds, the
agonist 5-nonyloxytryptamine (5-NT), found that its activity prevented the entry of chikungunya
virus, mouse hepatitis virus, coronavirus, and reovirus into host cells [91]. Furthermore, a
number of other viruses, including dangerous pathogens, HIV, Marburg virus, and ebolavirus,
are known to use other GPCRs to gain entry into host cells [92]. Not only does the relevance of
GPCRs in viral infections suggest the likelihood of these receptors as therapeutic targets of
antivirals [92], but the findings of reovirus infectivity inhibition by 5-HTR targeting drugs
through a high-throughput screening by ICW [90] and the implication of anti-JCPyV properties
by many similar drugs in the experiments presented here, highlights the potential of the ICW
platform in the discovery and characterization of new therapeutic agents.
Activation of the 5-HTRs is known to initiate cellular signaling pathways that result in the
movement of calcium ions into the cytoplasm to act as secondary messengers [91]. Cellular
signaling within cells via calcium ions is widespread and multifaceted and as such, has been
implicated in numerous stages of viral lifecycles. The role of calcium in viral infections can be
discussed in the context of direct viral association, membrane ion permeability, and calcium
mediated signaling pathways [53]. The reliance of JCPyV on calcium ions in all three of these
areas has been documented in the literature [54, 93] and explored in yet unpublished work
from the Maginnis lab [62].The capsid of JCPyV is known to require calcium ions in order for
proper viral uncoating at later stages of trafficking within host cells to occur [93]. A virally
encoded protein, agnoprotein, has previously been shown to act as a viroporin, increasing the
permeability at the plasma membrane of host cells to calcium ions in order to spur cell lysis and
the release of viral progeny [54]. Finally, preliminary results have suggested a reliance on
calcium ion release from the ER to the cytoplasm during JCPyV infection [62]. It is expected that
this calcium release activates downstream effectors, namely calmodulin and calcineurin, to the
benefit of the virus. In this working model, calcineurin activation of NFAT and calmodulin
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stabilization of the 5-HTRs at the cellular membrane surface, help to drive viral replication and
increase host cell susceptibility to infection [56, 62].
The many distinct roles suggested for calcium ions and the signaling events they
mediate within JCPyV infected cells is of great interest in light of the results of the drug screen
experiments presented here, as several candidate drugs effecting cell membrane calcium
permeability in multiple ways were implicated. These included drugs that target cell surface
calcium ion channels, as well as cell surface potassium channels, and ryanodine receptors
(responsible for calcium movement across the membrane of the ER [94]). Despite these
different targets, the actions of these drugs all appear to prevent movement of calcium ions
into the cytoplasm, whether from the ER or the extracellular environment, where it can
mediate the events JCPyV has apparently evolved to usurp this function for viral infection. The
identification of the antiviral effects of these drugs by ICW, in addition to their potential role in
therapeutic development, could present researchers with new compounds to help investigate
and elucidate the importance of currently scrutinized cellular pathways in the infectious viral
lifecycle.
The overlap of candidate drug function with JCPyV related cellular pathways was of
particular importance in prioritizing drug candidates for validation in order to increase the
chance of initial success in recapitulating the observed antiviral effect from the drug screen.
Given the pathology of PML within the CNS, we also reasoned that potential therapeutics must
be able to cross the BBB if they were to be viable clinical options. This rationale was consistent
with a previous screening of drugs against JCPyV [77]. To this end, the candidate drug
topiramate was selected for validation. Topiramate is an anticonvulsant and antimigraine drug
known to inhibit multiple signaling pathways, including that of calcium ions via ion channel
blockage. This particular mechanism and it activity within the CNS contributed to its selection
for further validation [95]. Interestingly, topiramate is prescribed in some cases of PML in which
plaque formation has resulted in seizures [96].
Although initial validation attempts did not show a dose-dependent decrease in JCPyV
infection in cells treated with topiramate at concentrations as high as 200 μM, a statistically
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significant reduction in infection of approximately 35% was observed (Figure 11). While further
characterization and optimization of assays for the potential anti-JCPyV activity of topiramate
are necessary, it is possible that increased concentrations of the drug may further reduce viral
infection, resulting in both a dose response and more biologically significant results.
While the remainder of the candidate drugs may have functionalities not implicated in
JCPyV infection, it is possible these drug functions could shine light on host cell pathways not
currently understood to impact the ability of JCPyV to carry out a productive infections. This
possibility is strengthened by what appears to be trends in the results, namely, the reduced
infectivity observed in the presence of multiple drugs of related function. In the experiments
conducted here, this trend was seen in cases of multiple inhibitors of histamine receptors (3),
as well as drugs known to impact estrogen signaling (at least two) reducing JCPyV infection in a
statistically significant manner. Both of these classes of drugs have demonstrated antiviral
activity against influenza viruses [97, 98]. While it is impossible to say without additional
validation of these results that these drugs and their documented mechanisms of action are
indeed effective at reducing the ability of JCPyV to carry out a productive infection, it is
certainly plausible. Such identification of previously unknown critical host cell pathways and
machinery would add an additional facet to the potential research utility of the ICW assay in
JCPyV research, an exciting prospect given the wide diversity of mechanisms and functionalities
of this study’s candidate antiviral compounds.
The use of a large-scale drug screens to identify previously unrecognized cellular
pathways as key players in viral infection is an active area in the field of virology. Previous work
published by a collaborator in this project, Dr. Bernardo Mainou, identified a key role played by
microtubules and dynein 1, as well as the 5-HTR class of receptors, in reovirus infection of HeLa
S3 cells when screening that virus against the same drug library (the NIH-CC) used in this study,
using the same ICW platform [90, 91]. This precedent and the above rationale are suggestive
that further analysis and characterization of the candidate drugs whose mechanisms of action
do not appear to target known JCPyV related cellular functions, is warranted. The drug screen
serves as a starting point to identify potential compounds that inhibit infection and
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characterization of these compounds may reveal interesting, novel information about virushost cell interactions and thus improves our understanding of the viral infectious cycle.
Of the 658 drugs and compounds that did not meet the criteria to be considered
candidate antiviral agents, 75 were unable to be fully analyzed. This stems from the fact that, in
the assay conditions performed, these drugs reduced the cellular content of samples
significantly, indicating toxicity. This is an important reminder that in any high-throughput
experimentation, the resulting data represents only a snapshot image of the whole story. Since
it was only feasible to test one set of conditions across the drug screen, there is little doubt that
compounds with significant antiviral activity were missed, as the optimal assay conditions of
drugs across the library are certain to differ widely. This would imply that the remaining “noncandidate” drugs should warrant re-examination under varied circumstances, decreasing the
treatment concentration of these 75 apparently toxic drugs, while increasing the treatment
concentration of the non-toxic, non-candidates. Still, this re-assessment of the NIH-CC is well
within reach of the ICW platform. Moreover, this assay will also allow for screens of any
number of libraries or collections of drugs and compounds. The experimentation made
accessible to researchers by the ICW, and its expanding use in the field of virology, makes the
ICW an invaluable tool in the search for antivirals against JCPyV and other viral pathogens.
The ICW offers some important benefits as a tool in laboratory research of JCPyV and
other viruses. Chief among these benefits is the high-throughput nature of an assay that fully
automates the process of gathering viral infectivity data, freeing the efforts of researchers and
increasing the rate of data acquisition, and hopefully, the rate of antiviral therapeutic
development. Moreover, automated data acquisition removes all observer bias from the results
of experiments, helping to reduce any doubt in experimental reproducibility. In addition, the
process by which the LI-COR Odyssey CLx completes full field scanning of samples provides data
from an entire sample population rather than representative sections of a population,
producing results that are a more complete picture. The assay is not without its limitations
though. Infectivity data produced through this method does not actually make determinations
of cellular infectivity, it only provides data on the relative amounts of protein present in a
sample. When assayed for a viral protein products, this method can provide insight into relative
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infectivity changes, but not absolute changes. This means that the ICW requires preliminary
experimentation and user familiarization prior to its use in new applications, as well as result
validation to ensure the efficacy of results. Taken together, the ICW represents a new tool in
the repertoire of virologist that provides experimental possibilities that were not easily
adaptable to traditional methodologies but it is best viewed as augmenting these methods, not
replacing them.
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APPENDIX A
Table A. Drugs Included in the NIH-CC
Daunorubicin
hydrochloride
Meloxicam
Aminoglutethimide
Methazolamide
Priscoline hydrochloride
Hydrocortisone
Doxycycline

Cefixime trihydrate
Mecillinam
Cladribine
Docetaxel
Cyproheptadine
hydrochloride
Rolipram
Chlordiazepoxide

SR 57227A
Dolasetron mesylate
Enalaprilat
Zolmitriptan
Nitrazepam
Oxymetholone
Telithromycin
Prednisolone sodium
succinate

Valproic acid
Nicardipine
hydrochloride

Corticosterone

Proxymetacaine
Terbutaline sulfate
Gatifloxacin
Pyrazinamide
Ethionamide

Clomifene citrate
Tetracycline
Sulfisoxazole
Ethynylestradiol
Levofloxacin

Lovastatin
Methocarbamol
Clopidogrel
Phenoxybenzamine
hydrochloride
Loperamide
hydrochloride
S(-)-Timolol maleate
Penicillin V
Flunisolide
DL-Penicillamine
Minoxidil
Orphenadrine
hydrochloride
Furosemide
5-Fluorouracil
Procyclidine
hydrochloride
Pyridostigmine bromide

4-Phenylbutyric acid
Rabeprazole
Naphazoline hydrochloride

Modafinil
SKF 83566
hydrobromide
Parecoxib sodium
Stiripentol
Sibutramine
Vindesine sulfate
Palonosetron
hydrochloride
Naproxen sodium
Mepirizole

Rutin

Methylandrostenediol

Edrophonium chloride
Letrozole
Ethacrynic acid
Zucapsaicin
Aminolevulinic acid
Nortriptyline hydrochloride

Tibolone
Dichloroacetic acid
Tryptoline
Diazepam
Ornidazole
Voriconazole

Moclobemide
Omeprazole
Taxifolin-(+/-)

Glycopyrronium bromide
Pravastatin sodium
Bestatin

CCPA
Nitrendipine

PD 81723
Isradipine

Demeclocycline
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Table A. Continued

Tolazamide
Metyrapone
Pindolol
Probenecid
Fexofenadine
hydrochloride
Hydrochlorothiazide
Folic acid
Prednisone
Penicillin G potassium
Eryped
Medrysone
Methylprednisolone
Doxazosin
Azathioprine
Hydroxyzine pamoate
Cortisol 21-acetate
Mafenide acetate
Medroxyprogesterone
17-acetate
Labetalol hydrochloride
Triamcinolone acetonide
Thiabendazole
Prednisolone
Ofloxacin
Prilocaine hydrochloride
Nadolol
Felodipine
Carbidopa
Midodrine hydrochloride
Nabumetone
Tropicamide
Propafenone
Fluorometholone
Thiothixene
Cetirizine
Indomethacin hydrate

Repaglinide
Vincristine sulfate
Mestranol
Crotamiton

Benactyzine
hydrochloride
Argatroban
Brucine
Cefdinir

Flumazenil
Desoximetasone
Mevastatin
Ebselen
Naftopidil
CGS 12066B dimaleate
Atracurium besylate
Ursodeoxycholic acid
Estrone 3-sulfate sodium salt
Bicalutamide
Halometasone monohydrate
TFMPP hydrochloride
Ozagrel hydrochloride

Carmofur
Homoveratrylamine
Artemether
Montelukast sodium
Zalcitabine
Tacrolimus
Tegafur
Itraconazole
Cefaclor
Tocainide
Methyltestosterone
Beclomethasone
Nialamide

Benidipine hydrochloride
Nefazodone hydrochloride
Sertraline hydrochloride

Valdecoxib
Raltitrexed
Ipidacrine
Pilocarpine
Indinavir sulfate
hydrochloride
Pioglitazone hydrochloride
Nicorandil
Epirubicin hydrochloride
Famciclovir
Amiodarone
Hexamethylenebisacetamide hydrochloride
Moxifloxacin hydrochloride
Nizatidine
Venlafaxine hydrochloride
Topotecan hydrochloride
AM 404
Salmeterol
Irinotecan hydrochloride
SDM25N hydrochloride
Buflomedil hydrochloride
Calcipotriol
Doxorubicin hydrochloride
Lacidipine
CGS 15943
Ketoconazole
Imatinib mesylate
Pergolide mesylate
Perospirone hydrochloride
Dofetilide
Milnacipran hydrochloride
L-694,247
Rofecoxib
Nalidixic acid
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Table A. Continued
Promethazine
hydrochloride
Fluoxetine hydrochloride
Minocycline
hydrochloride
19-Norethindrone
acetate
Altretamine
Ipratropium bromide
Fludarabine
Rifapentine
Hexachlorophene
Oxacillin sodium
Acitretin
Acyclovir
Betamethasone
Oxybutynin
hydrochloride
Diflunisal
Nicotine
Dexamethasone
6-Azauridine
Atomoxetine
hydrochloride
Phenothiazine
Dipyridamole

Rosiglitazone maleate
Nafadotride

Pazufloxacin
Honokiol

Escitalopram oxalate

Maltol

Tropisetron hydrochloride
Fenoldopam mesylate
Tosufloxacin tosilate
Vardenafil citrate
Physostigmine hemisulfate
Nornicotine
Loxoprofen sodium
Tegaserod maleate
Trimebutine maleate
Calcitriol

Levocetirizine
Etomidate
Megestrol acetate
GR 89696 fumarate
Lamotrigine
Rifaximin
Irsogladine maleate
Lofexidine hydrochloride
Benazepril hydrochloride
Nobiletin

Progesterone
Urapidil hydrochloride

Irbesartan
Etomoxir
Tripelennamine
hydrochloride
Synephrine
Diclofenac sodium

Enrofloxacin
Idebenone
Tamoxifen

Betaxolol hydrochloride
5-Fluoro-2-pyrimidone
Mosapride citrate
1,1-Dimethyl-4phenylpiperazinium iodide
Penciclovir
Pizotyline maleate
Dexchlorpheniramine
maleate
Formoterol fumarate
dihydrate
Cinanserin
Ropivacaine hydrochloride

Azithromycin

Prochlorperazine maleate

Eszopiclone
Taxifolin-(+)
GR 79236
5-Nonyloxytryptamine
hydrochloride

Pefloxacin mesylate
Terbinafine hydrochloride
Oxyphenonium bromide

Vecuronium bromide
Idarubicin hydrochloride
Tramadol hydrochloride
Chlorpheniramine
maleate
Naltrindole
hydrochloride hydrate
Epigallocatechin gallate
Pramipexole

Hyperoside

Selegiline hydrochloride

6-Aminoindazole
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Bupropion hydrochloride
Cefpodoxime proxetil
Azelastine hydrochloride
Meropenem

Table A. Continued
Chloramphenicol
Ormetoprim

Doxepin hydrochloride

Haloperidol hydrochloride
Lamivudine
Alosetron
monohydrochloride
Loratadine
Dextromethorphan
hydrobromide,
monohydrate

Rifabutin

Maprotiline hydrochloride

Atropine
11-Deoxycortisol

Riluzole hydrochloride
Pentoxifylline

Methotrexate trihydrate

Fluperlapine

Clobenpropit
Tranilast
Mesna
Nafcillin sodium
Isoproterenol
hydrochloride
Ketoprofen

MK 886
Pancuronium dibromide
Cisapride hydrate
Fluvoxamine maleate

Propofol
L-Thyroxine
Cortisone

Esmolol hydrochloride
Piribedil hydrochloride
Granisetron hydrochloride

7-Nitroindazole
Benproperine phosphate

Efavirenz
Nelfinavir mesylate

Bumetanide
SB 205607
dihydrobromide
Levonorgestrel
Miglitol
Buspirone hydrochloride
Raloxifene hydrochloride
Methylprednisolone
acetate
Troxipide

Ticlopidine hydrochloride

Sulfacetamide
Phenprobamate

Lansoprazole
DuP 697

2-Chloroadenosine
Cilastatin sodium
Lorazepam
Phenelzine sulfate
Prazosin hydrochloride
hydrate
Amiloride hydrochloride
hydrate
Valaciclovir
hydrochloride
Trazodone hydrochloride
R(+)-SCH-23390
hydrochloride
Remacemide
hydrochloride
Sumatriptan succinate
Tolterodine tartrate
Itavastatin calcium

Losartan potassium
(-)-Cotinine
Duloxetine hydrochloride
Clotrimazole
Fluticasone propionate

Donepezil hydrochloride
Bifonazole
Procarbazine
hydrochloride
Droperidol
Flecainide hydrochloride
Diphenoxylate
hydrochloride
Dextrorphan D-tartrate
Anagrelide
hydrochloride
Galanthamine
hydrobromide
Pemolide
Lidocaine
Ritonavir
Disulfiram

Itopride hydrochloride
Moxonidine hydrochloride

Quetiapine fumarate
Salbutamol sulfate
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Table A. Continued
MDL 73005EF
hydrochloride

Nifekalant hydrochloride

Rufloxacin hydrochloride
Benztropine mesylate
Levosulpiride
Nitazoxanide
Oxiconazole nitrate
Clomipramine
hydrochloride

Indatraline hydrochloride
L-NMMA acetate
Mestanolone
Dactinomycin
Amlodipine

Piperacillin sodium

Artesunate

Quinidine
Resveratrol
Dehydroepiandrosterone
Lomifylline
Secnidazole
Captopril
Dilantin

Olopatadine hydrochloride
Altanserin hydrochloride
5-Methoxytryptamine
Cephalexin hydrate
Actarit
Linopirdine dihydrochloride
Cefatrizine propylene glycol

Nicotinamide

Tremulacin

5-Azacytidine

Valsartan

Enalapril maleate
Bethanechol chloride
Secoisolariciresinol
Benzylimidazole
Budesonide
Zardaverine

Zeranol
Oxcarbazepine
Desloratadine
Amlexanox
Tadalafil
Aripiprazole

Loxapine succinate
Propranolol
hydrochloride

Citalopram hydrobromide

Acarbose
Carbamazepine
Dantrolene sodium
Naloxone hydrochloride

Triptolide
Tinidazole
Amisulpride
Triclabendazole

Mirtazapine

P1075

Bifemelane
hydrochloride
Scopolamine
hydrobromide
Nifedipine
Tacrine hydrochloride
Indirubin
Oligomycin A
Roxatidine acetate
hydrochloride
Esomeprazole
magnesium
Trifluoperazine
hydrochloride
Glimepiride
Cetraxate hydrochloride
Huperzine A
Metronidazole
19-Nortestosterone
Beta-estradiol
Ranolazine
dihydrochloride
Nalbuphine
hydrochloride
(+/-)-Vesamicol
hydrochloride
E-4031 dihydrochloride
Cytarabine
Raclopride
Paroxetine maleate
Famotidine
Dexbrompheniramine
maleate
Ketotifen fumarate
Rimcazole
dihydrochloride
Goserelin acetate
Spironolactone
Carbinoxamine maleate
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Table A. Continued
Dehydrocholic acid
Piceid
Torasemide

Olmesartan medoxomil
Ketorolac tromethamine
Linezolid

Prostaglandin E1

Otenzepad

Nisoldipine

Didanosine

Chlorambucil
Ampicillin sodium
Dapsone
Cyclophosphamide
hydrate
Miconazole nitrate

Milrinone
Tiagabine hydrochloride
Nevirapine

Phylloquinone
Ondansetron
Mupirocin
Thioridazine
hydrochloride
19-Norethindrone

Azasetron hydrochloride
Bisoprolol fumarate
Olanzapine

Celecoxib
Floxuridine
Indapamide
Imipramine
hydrochloride
Quinapril hydrochloride

Ramipril
Pterostilbene
Cerivastatin sodium

Perphenazine
Norfloxacin
Spectinomycin
Dicloxacillin sodium
Procaine hydrochloride

Lofepramine
Clarithromycin
Benzbromarone
Clonidine hydrochloride
Clofazimine

Griseofulvin
Mexiletine hydrochloride
Fluocinolone acetonide
21-acetate
Fenofibrate
Symmetrel

Levetiracetam
Isoquercitrin

Chlorothiazide
Flubendazole
Beclomethasone
dipropionate
Testosterone
Homoharringtonine
LY 171883
Ibuprofen
Zacopride hydrochloride
hydrate
Diphenylcyclopropenone

D-Cycloserine
Alprazolam
Pantoprazole sodium

Anastrozole
Pirenperone
Stanozolol

Ifenprodil hemitartrate
Latanoprost

Picrotin - Picrotoxinin
Telmisartan

Ampiroxicam
Xanthinol nicotinate
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Meclizine hydrochloride
Ganciclovir
Praziquantel
Meclofenamic acid
sodium salt
Memantine
hydrochloride
(+)-cis-Diltiazem
hydrochloride
Chloroxine
Estradiol valerate
Nitrofurantoin
Cefazolin sodium
Chlorpromazine
hydrochloride
Isotretinoin
Warfarin sodium
Cimetidine
Gemfibrozil
Dicyclomine
hydrochloride
Fluconazole
Zolpidem tartrate

Table A. Continued
Acetazolamide
(+/-)-Norepinephrine
hydrochloride
Flumadine hydrochloride
Amitriptyline
hydrochloride
Phentolamine monohydrochloride
Cefotaxime sodium
Desipramine
hydrochloride
Etodolac
Clozapine
Tetrahydrozoline
hydrochloride
Allopurinol
Busulfan
Nateglinide

Zafirlukast

Felbamate

Pidotimod
Ezetimibe

Verapamil hydrochloride
Rolitetracycline

AM-251

3-Pyridinemethanol

Fenpiverinium bromide
Flurbiprofen

3'-Deoxydenosine
Procysteine

Exemestane
Orlistat
Medroxyprogesterone

Doxylamine succinate
Etoposide
Zonisamide

Rizatriptan benzoate
Icariin
Alfuzosin
Finasteride

Podofilox
Hydroflumethiazide
3,5,3'-Triiodothyronine

2-Pyridylethylamine
Topiramate
Vinorelbine tartrate

Zidovudine
Chlorzoxazone

Nimodipine
HTMT dimaleate

Acebutolol hydrochloride
Propantheline bromide
Ipriflavone
Trihexyphenidyl
hydrochloride
Ru 24969 hemisuccinate
Flucytosine
Mepivacaine
hydrochloride
Carvedilol
Naltrexone hydrochloride
Cefuroxime

Dihydrexidine hydrochloride
Ethylestrenol
Temozolomide

Balsalazide
Digoxin
Racecadotril
Piroxicam
Fluphenazine
dihydrochloride
RU-486
Deferiprone
Lomerizine
dihydrochloride
Pinacidil monohydrate
Methylperone
hydrochloride
Diazoxide
Lobeline hydrochloride

Zaleplon
Risperidone
Carisoprodol

Oxaprozin
Gabexate mesilate
Nimetazepam

Ranitidine hydrochloride
Fluocinolone acetonide
Methyldopa
Theophylline
Hydrocortisone
Acetylcholine chloride
hemisuccinate
Lincomycin hydrochloride Triamterene
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Primaquine diphosphate
Amcinonide
Chlorpropamide
Mefenamic acid
Flutamide
Tolbutamide

Table A. Continued
Stavudine
Propylthiouracil
Econazole nitrate
Pyrimethamine
Ethambutol
Amoxicillin
Primidone
Toremifene citrate
Pralidoxime chloride

Molindone hydrochloride
Clobetasol propionate
Procainamide hydrochloride
Racepinephrine
Triclosan
Mepenzolate bromide
Amoxapine
Sulindac
Hydrocortisone 17-valerate

Chlorthalidone
Glipizide
Mercaptopurine

Mebendazole
Atenolol
Dopamine hydrochloride

Duvadilan
Isoniazid

Metaproterenol
Methoxsalen
Metoclopramide
hydrochloride
Thalidomide
Disopyramide phosphate

Albendazole
Terazosin
Cromolyn sodium
Oxytetracycline
hydrochloride
Ribavirin
Sulfasalazine
Diphenhydramine
hydrochloride
Sulfamethoxazole
Kitasamycin

Brimonidine

Doxapram hydrochloride
Tizanidine hydrochloride
Loteprednol etabonate
Cefoxitin sodium
Cortisone acetate
Methimazole
Prednisolone acetate
Mesalamine
Saquinavir mesylate
Midazolam
hydrochloride
Fluvastatin
Danazol
Mitoxantrone
hydrochloride
Glyburide
trans-Retinoic acid
Sulfinpyrazone
Rifampicin

Nicotinic acid
Bendrofluazide

Vidarabine
Mefloquine
hydrochloride
Mesoridazine besylate

Zileuton
Sotalol hydrochloride

Trimethoprim
Simvastatin
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APPENDIX B
Table B. Candidate Drugs Identified in Screen Against JCPyV
Drug Name
Nicardipine hydrochloride
Loperamide hydrochloride
Pindolol
Triamcinolone acetonide
Cetirizine
Oxacillin sodium
Lomifylline
Secoisolariciresinol
Benzylimidazole
Dantrolene sodium
Isoniazid
Moclobemide
Omeprazole
CCPA
Naftopidil
CGS 12066B dimaleate
Milrinone
Telmisartan
Ramipril
Ampiroxicam
Xanthinol nicotinate
Levetiracetam
Isoquercitrin
Fenpiverinium bromide
Flurbiprofen
Exemestane
Rizatriptan benzoate
Topiramate
Nimodipine

Function
Coronary and cerebral vasodilator
Mu opioid receptor agonist
Beta-adrenoceptor blocker
Synthetic glucocorticoid steroid
Antagonist of histamine (H1) receptor
(second generartion)
Beta-lactam antibiotic
Data limited (potential vasodilator)
Plant based polyphenol of unknown
mechanism
May prevent DNA/RNA synthesis
Muscle relaxor- targets RyR1 and
prevents calcium release
Antituberculosis agent
Reversible inhibitor of monoamine
oxidase A
Hydrogen/Potassium ATPase inhibitor
Specific receptor agonist for
the adenosine A1 receptor
α1A-adrenoceptor antogonist
Selective serotonin 1B receptor agonist
PDE3 inhibitor
Angiotensin II receptor blocker
Angiotensin converting enzyme (ACE)
inhibitor
Prostaglandin-endoperoxide synthase
inhibitor (NSAID)
Vasodilator peripheral and cerebral
Targets SV2A at synapse (antiepileptic)
Unknown mechanism (flavonoid)
Anticholinergic agent (limited data)
Cyclooxygenase inhibitor (NSAID)
Aromatase inhibitor
Selective 5-hydroxytryptamine 1B/1D (5HT1B/1D) receptor agonist
Calcium channel blocker (Antiepileptic)
Calcium channel blocker (cerebral
vasodilator)
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Table B. Continued
HTMT dimaleate
Danazol
Cimetidine
Isradipine
Pilocarpine hydrochloride
Nicorandil
Pergolide mesylate
Bifonazole
Nifedipine
Trifluoperazine hydrochloride
Beta-estradiol
Ranolazine dihydrochloride
Paroxetine maleate

Histamine (H1) receptor agonist
Synthetic steroid (androgen), reduces
estrogen production
Antagonist of histamine (H2) receptor
Calcium channel blocker (coronary,
peripheral, and cerebral vasodilator)
Cholinergic agonist (target muscarinic
receptors)
Potassium channel activators (prevents
calcium buildup within cell)
Dopamine receptor agonist
Imidazole
Blocks Ca activated K channel
Dopamine receptor blocker
(antipsychotic), Inhibitor of calmodulin
Activates estrogen receptor
Partial fatty acid oxidation (pFOX)
inhibitor
Selective serotonin reuptake inhibitor
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